Ouch: Eli Lilly is walking away from Adocia deal and its ultra-fast insulin — for the second time
A little more than two years ago, Eli Lilly admitted it had made a big mistake in dumping Adocia (Paris:ADOC) and their pact on the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
